Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: Role of CYP3A and P-glycoprotein

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 3, 2003, Pages 1161-1171

  Kumar, Sanjeev ^a   Kwei, Gloria Y ^a   Poon, Grace K ^a   Iliff, Susan A ^a   Wang, Yanfeng ^a   Chen, Qing ^a   Franklin, Ronald B ^a   Didolkar, Varsha ^a   Wang, Regina W ^a   Yamazaki, Masayo ^a   Chiu, Shuet Hing Lee ^a   Lin, Jiunn H ^a   Pearson, Paul G ^a   Baillie, Thomas A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CYTOCHROME P450 3A; GLYCOPROTEIN P; MRK 1; MULTIDRUG RESISTANCE PROTEIN 1; N METHYL N [4 [3 BENZYL 1 ETHYL (1H) PYRAZOL 5 YL]PIPERIDIN 1 YL]METHYL 4 (3 FLUOROPHENYL)CYCLOPENT 1 YLAMINO 3 METHYLBUTANOIC ACID; QUINIDINE; RITONAVIR; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; MEAN RESIDENCE TIME; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT; RHESUS MONKEY;

ADMINISTRATION, ORAL; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HAPLORHINI; HIV PROTEASE INHIBITORS; INTESTINAL ABSORPTION; MALE; OXIDATION-REDUCTION; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; PROTEIN BINDING; PYRAZOLES; QUINIDINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CCR5; RITONAVIR; VALINE;

EID: 0037373091     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.045096     Document Type: Article

References (39)

1. Achira M, Suzuki H, Ito K, and Sugiyama Y (1999) Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P450 3A4. AAPS Pharmsci 1:1-10.
2. Alsenz J, Steffen H, and Alex R (1998) Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res (NY) 15:423-428.
3. Balfe P, Churcher Y, Penny M, Easterbrook PJ, Goodall RL, Galpin S, Gotch F, Daniels RS, and McKeating JA (1998) Association between a defective CCR-5 gene and progression to disease in HIV infection. AIDS Res Hum Retroviruses 14:1229-1234.
4. Barry M, Gibbons S, Back D, and Mulcahy F (1997) Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 32:194-209.
5. Barry M, Mulcahy F, Merry C, Gibbons S, and Back D (1999) Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 36:289-304.
6. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR (1997) Change in coreceptor use correlates with disease progression in HIV-1 -infected individuals. J Exp Med 185:621-628.
7. Cummins CL, Jacobsen W, and Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045.
8. Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, and Wrighton SA (1999) Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 290:854-862.
9. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10:1093-1095.
10. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al. (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature (Lond) 381:661-666.
11. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, et al. (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (Lond) 381:667-673.
12. Eagling VA, Back DJ, and Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
13. Eckert DM and Kim PS (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70:777-810.
14. Finke P, Oates B, Meurer L, Loebach J, Parker K, Hale J, Lynch C, Budhu R, Gentry A, Caldwell C, et al. (2002) The discovery of potent human CCR5 antagonists based on a cyclopentane scaffold. Inflammation Research Association 11th National Convention Proceedings; 2002 October 5-10; Lake George, New York.
15. Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd ed, Marcel-Dekker Inc., New York.
16. Gutmann H, Fricker G, Drewe J, Toeroek M, and Miller DS (1999) Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56:383-389.
17. Hsu A, Granneman R, and Bertz RJ (1998) Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275-291.
18. Iyer L, Ramirez J, Shepard DR, Bingham CM, Hossfeld DK, Ratain MJ, and Mayer U (2002) Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol 49:336-341.
19. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Investig 101:289-294.
20. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. (1999) Interrelationships between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (NY) 16:408-414.
21. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, and Dey S (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
22. Lin JH, Chiba M, Balani SK, Chen I-W, Kwei GYS, Vastag KJ, and Nishime JA (1996) Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immune-deficiency virus protease inhibitor. Drug Metab Dispos 24:1111-1120.
23. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, and Landau NR (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377.
24. Mei Q, Tang C, Assang C, Lin Y, Slaughter D, Rodrigues AD, Baillie TA, Rushmore TH, and Shou M (1999) Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291:749-759.
25. Moore JP and Stevenson M (2000) New targets for inhibitors of HIV-1 replication. Nat Rev: Mol Cell Biol 1:40-49.
26. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, and Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
27. Profit L, Eagling VA, and Back DJ (1999) Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13:1623-1627.
28. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, et al. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028-4033.
29. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al. (1994) Disruption of the mouse Mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
30. Schinkel AH, Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Investig 97:2517-2524.
31. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, and Borst P (1995) Absence of the Mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J Clin Investig 96:1698-1705.
32. Sparreboom A, Asperen JV, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, and Tellingen OV (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (taxo1) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA. 94:2031-2035.
33. Tang W, Stearns RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, et al. (1999) Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J Pharmacol Exp Ther 291:1068-1074.
34. Torres RA and Barr M (1997) Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 336:1531-1532.
35. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, and van Tellingen O (1996) Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst 88:994-999.
36. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, and Shader RI (1998) Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 38:106-111.
37. Wacher VJ, Wu C-Y, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
38. Wandel C, Kim RB, Kajiji S, Guengerich FP, Wilkinson GR, and Wood AJJ (1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59:3944-3948.
39. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, and Lin JH (2001) In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 296:723-735.